Monte Rosa Therapeutics Statistics
Total Valuation
GLUE has a market cap or net worth of $260.50 million. The enterprise value is $107.93 million.
| Market Cap | 260.50M |
| Enterprise Value | 107.93M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GLUE has 61.15 million shares outstanding. The number of shares has increased by 21.90% in one year.
| Shares Outstanding | 61.15M |
| Shares Change (YoY) | +21.90% |
| Shares Change (QoQ) | +5.56% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 80.51% |
| Float | 28.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 244.83 |
| Forward PS | 40.61 |
| PB Ratio | 1.71 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 101.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.30.
| Current Ratio | 4.82 |
| Quick Ratio | 4.80 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -74.10% and return on invested capital (ROIC) is -72.84%.
| Return on Equity (ROE) | -74.10% |
| Return on Assets (ROA) | -49.10% |
| Return on Capital (ROIC) | -72.84% |
| Revenue Per Employee | $8,000 |
| Profits Per Employee | -$1.02M |
| Employee Count | 133 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GLUE has paid $421,000 in taxes.
| Income Tax | 421,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.06% in the last 52 weeks. The beta is 1.38, so GLUE's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | -39.06% |
| 50-Day Moving Average | 4.20 |
| 200-Day Moving Average | 4.92 |
| Relative Strength Index (RSI) | 51.94 |
| Average Volume (20 Days) | 296,487 |
Short Selling Information
The latest short interest is 2.56 million, so 4.19% of the outstanding shares have been sold short.
| Short Interest | 2.56M |
| Short Previous Month | 1.98M |
| Short % of Shares Out | 4.19% |
| Short % of Float | 8.94% |
| Short Ratio (days to cover) | 9.84 |
Income Statement
In the last 12 months, GLUE had revenue of $1.06 million and -$135.28 million in losses. Loss per share was -$2.51.
| Revenue | 1.06M |
| Gross Profit | 1.06M |
| Operating Income | -144.00M |
| Pretax Income | -134.86M |
| Net Income | -135.28M |
| EBITDA | -127.89M |
| EBIT | -134.86M |
| Loss Per Share | -$2.51 |
Balance Sheet
The company has $197.76 million in cash and $45.18 million in debt, giving a net cash position of $152.57 million or $2.50 per share.
| Cash & Cash Equivalents | 197.76M |
| Total Debt | 45.18M |
| Net Cash | 152.57M |
| Net Cash Per Share | $2.50 |
| Equity (Book Value) | 152.52M |
| Book Value Per Share | 2.49 |
| Working Capital | 157.74M |
Cash Flow
In the last 12 months, operating cash flow was -$58.56 million and capital expenditures -$11.18 million, giving a free cash flow of -$69.74 million.
| Operating Cash Flow | -58.56M |
| Capital Expenditures | -11.18M |
| Free Cash Flow | -69.74M |
| FCF Per Share | -$1.16 |
Margins
Gross margin is 100.00%, with operating and profit margins of -13,533.74% and -12,714.47%.
| Gross Margin | 100.00% |
| Operating Margin | -13,533.74% |
| Pretax Margin | -12,674.91% |
| Profit Margin | -12,714.47% |
| EBITDA Margin | -12,020.02% |
| EBIT Margin | -12,674.91% |
| FCF Margin | -6,554.79% |
Dividends & Yields
GLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.90% |
| Shareholder Yield | -21.90% |
| Earnings Yield | -51.93% |
| FCF Yield | -26.77% |
Analyst Forecast
The average price target for GLUE is $12.25, which is 187.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.25 |
| Price Target Difference | 187.56% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GLUE has an Altman Z-Score of -1.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.67 |
| Piotroski F-Score | 2 |